4.8 Article

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours

期刊

NATURE COMMUNICATIONS
卷 6, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms8227

关键词

-

资金

  1. Swiss National Science Foundation (SNF) [PZ00P3_136612/1]
  2. European Society for Medical Oncology (ESMO)
  3. Swiss Bridge Award
  4. European research council [ERCsg 261342]
  5. AIRC grant [IG-14180]
  6. [ERCsg 260316]
  7. Swiss National Science Foundation (SNF) [PZ00P3_136612] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy. Currently, there are only a limited number of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells. Here we developed a chemogenomic screening to identify compounds that enhance senescence in PTEN-deficient cells without affecting normal cells. By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target. Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3. CK2 upregulation in Pten null tumours affects the stability of Pml, an essential regulator of senescence. However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumours. Taken together, our screening strategy has identified a novel STAT3-CK2-PML network that can be targeted for pro-senescence therapy for cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据